Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE pilot study of CER-001 to prevent sepsis-induced acute kidney injury
2020-004202-60Phase 2Completed
- Sponsor
- ABIONYX Pharma
- Start
- Aug 2021
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised trial of CER-001 in sepsis and acute kidney failure (AKF) (3 arms), sponsored by ABIONYX Pharma. Primary endpoints: Optimal dose based on safety, Onset of acute kidney injury and 1 more. Started Aug 2021; status: completed.
02
Drugs
CER-001
03
Conditions
sepsisacute kidney failure (AKF)
Beyond the preview
Go deeper on 2020-004202-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004202-60.